VOLUME 22 | NUMBER 12 | DECEMBER 2016 nature medicine a r t i c l e s Checkpoint blockade therapies prove that an endogenous immune response can regress human tumors, but significant responses remain restricted to a minority of patients [1] [2] [3] [4] [5] . To avoid immune-mediated clearance, advanced tumors co-opt an array of immunosuppressive pathways, which are unlikely to be overcome by intervention at a single signaling checkpoint 4, [6] [7] [8] [9] . Combining checkpoint blockade with other agents may improve response rates [10] [11] [12] , and immunotherapies that use three or more agents in tandem are already in clinical testing [13] [14] [15] [16] . However, even in preclinical models, complete tumor rejection is usually achieved only by treating very small tumors and/or by treating the tumors at very early times preceding the establishment of a fully developed tumor microenvironment, unless adoptive transfer of ex-vivo-expanded T cells is used 17, 18 . Autochthonous tumors induced in genetically engineered animals, which may generate immunosuppressive networks more akin to those of human tumors, are also generally refractory to immunotherapy 19, 20 . As such, the general characteristics of an endogenous immune response capable of reliably eradicating large immunosuppressive tumor burdens remain unclear.
a r t i c l e s
Checkpoint blockade therapies prove that an endogenous immune response can regress human tumors, but significant responses remain restricted to a minority of patients [1] [2] [3] [4] [5] . To avoid immune-mediated clearance, advanced tumors co-opt an array of immunosuppressive pathways, which are unlikely to be overcome by intervention at a single signaling checkpoint 4, [6] [7] [8] [9] . Combining checkpoint blockade with other agents may improve response rates [10] [11] [12] , and immunotherapies that use three or more agents in tandem are already in clinical testing [13] [14] [15] [16] . However, even in preclinical models, complete tumor rejection is usually achieved only by treating very small tumors and/or by treating the tumors at very early times preceding the establishment of a fully developed tumor microenvironment, unless adoptive transfer of ex-vivo-expanded T cells is used 17, 18 . Autochthonous tumors induced in genetically engineered animals, which may generate immunosuppressive networks more akin to those of human tumors, are also generally refractory to immunotherapy 19, 20 . As such, the general characteristics of an endogenous immune response capable of reliably eradicating large immunosuppressive tumor burdens remain unclear.
We recently reported that therapies combining tumor-specific antibodies and an interleukin (IL)-2 molecule with an extended half-life (IL-2 fused with either mouse serum albumin (MSA-IL-2) or the antibody Fc fragment) showed synergistic therapeutic effects in mouse models of cancer 21 . This combination was curative when administered with adoptive T cell therapy. We hypothesized that similar therapeutic results might be achieved in the setting of a wholly endogenous immune response by replacing T cell transfer with a powerful vaccine. To this end, we used a potent lymph-node (LN)-targeted vaccine composed of peptide antigens and CpG DNA conjugated to albumin-binding lipids. These amphiphile-vaccines reversibly bind to the albumin present in interstitial fluid and efficiently traffic to LNs, leading to robust T cell responses 22 . We also included systemic anti-PD-1 administration because of its capacity to enhance vaccine responses and further modulate the tumor microenvironment by blocking suppressive signals that dampen antitumor immunity 5, 8 . In multiple syngeneic tumor models, as well as in the Braf/Pten genetically engineered mouse model of melanoma, this quaternary combination immunotherapy cured a majority of mice with established tumors and elicited long-lived protective T cell memory responses.
RESULTS

Tumor regression by combination therapy
Motivated by the synergy observed between extended-half-life IL-2 and tumor-specific antibodies 21 and by our recent discovery of a strategy to efficiently target peptide vaccines to LNs 22 , we explored combination treatments bringing these reagents together with checkpoint blockade. To simplify reference to this four-component therapy, we designate combinations of these components by concatenated single initials A (tumor-antigen-specific antibody), I (MSA-IL-2), P (anti-PD-1) and V (amphiphile-vaccine). We first evaluated this combination treatment in three subcutaneous syngeneic tumor models: B16F10 melanoma, DD-Her2/neu (a mouse breast cancer line that expresses the transforming rat Erbb2 (also known as Her2/neu) oncogene) and TC-1 tumors, which express the human papilloma virus (HPV) onco-antigens E6 and E7. For each tumor, appropriate A and V components were selected (Fig. 1a) . Antibodies to melanoma-associated antigen tyrosinaserelated protein 1 (Trp1; targeted by the TA99 antibody) and Her2/neu (targeted by 7.16.4) were used to treat mice bearing the B16F10 and DD-Her2/neu tumors, respectively, whereas an antibody surrogate 2.5F-Fc (Fc fused with an engineered binding protein that recognizes the tumor-expressed α v β 3 , α v β 5 and α 5 β 1 integrins 23 ) was used to treat mice with TC-1 tumors. Amphiphile-peptide vaccines encoding the well-characterized immunodominant Trp2, Her2/neu and HPV E7 epitopes were synthesized ( Supplementary Fig. 1d-g and ref. 22 ). Tumor cells (10 6 ) were injected subcutaneously and allowed to grow for 8 d before initiation of therapy, resulting in tumor sizes of ~40-60 mm 2 at the initial time of treatment, depending on the tumor model. The protein components were injected intraperitoneally (i.p.), and the vaccine was administered subcutaneously (s.c.) at the base of the tail. Therapies were given once per week, with P and V being administered three times, and A and I being given five times (Fig. 1a) .
This AIPV regimen induced robust tumor regression and durable cures in 75% of the mice bearing B16F10 melanoma tumors (Fig. 1b) , whereas combinations of three or fewer of the AIPV components elicited weaker therapeutic responses, ranging from modestly reduced efficacy (AIP) to outcomes barely different from those of untreated tumors (APV) (Fig. 1b and Supplementary Fig. 2a,b,g ). Greater than 80% of AIPV-treated long-term survivors rejected a re-challenge with 10 5 B16F10 cells 2 months after cessation of therapy, suggesting formation of effective immunological memory (Fig. 1c) Similarly, in the DD-Her2/neu and TC-1 tumor models, >70% of mice achieved complete tumor rejection after treatment with AIPV, and 100% of the long-term survivors rejected tumors after re-challenge ( Fig. 1d-g and Supplementary Fig. 2c-f,h,i) . Triple combinations of AIPV components demonstrated substantially lower efficacy in primary tumor rejection, although each of the three tumor models showed a different hierarchy of efficacy with the ternary combinations. A limited exploration of alternate four-agent combinations revealed that anti-PD-1 could be replaced by an antibody specific for CTLA-4, but several other combinations failed to replicate AIPV in eliminating B16F10 tumors (Supplementary Fig. 3) . Notably, despite high rates of response, AIPV therapy was associated with minimal systemic toxicity, as mice did not show weight loss or substantial elevation in the amounts of liver enzymes in the blood (Supplementary Fig. 4a-c) .
Combination therapy affects immune cell infiltration into the tumor To understand the cellular and molecular mechanisms underlying the observed therapeutic effect of the quaternary combination therapy, we In b,c, n = 10 C57Bl/6 mice per group for APV, and n = 20 for all other groups. In d,e, n = 7 Balb/c mice for untreated and AIPV groups, and n = 5 for all other groups. In f,g, n = 8 C57Bl/6 mice per group. Data were compiled from two (DD-Her2/neu and TC-1) or three (B16F10) independent experiments. Arrows indicate treatment time points. *P < 0.05; **P < 0.01; ***P < 0.001; versus AIPV by log-rank (Mantel-Cox) test. further analyzed responses to AIPV therapy in the B16F10 model as representative of an immunosuppressive, poorly immunogenic tumor. AIPV treatment induced expansion of an interferon (IFN)-γ-producing Trp2-specific CD8 + T cell population in the blood of mice (Fig. 2a,b) ; abundance of these cells in treated animals correlated with vitiligo, which is associated with favorable responses to immunotherapy in the clinic 24 ( Supplementary Fig. 4d-f) . However, similar Trp2-specific T cell responses were elicited by AIV and IPV treatments, which failed to induce comparable therapeutic outcomes (Fig. 2b) . We thus looked for changes within tumors that correlated more closely with survival. Luminex-based quantification of intratumoral cytokines and chemokines revealed five clusters of co-regulated proteins, with many pro-inflammatory factors increased in tumors after treatment with effective therapies (Fig. 2c and Supplementary Fig. 5 ). We used partial least-squares regression (PLSR) to construct models using cytokines from each cluster to predict log 10 (tumor mass) values.
Analysis of the variance in tumor mass explained by each model revealed that cluster 3 cytokines captured the most variance ( Fig. 2d) and, therefore, provided the most predictive model. Variable importance in projection (VIP) scores identified four predictive biomarkers from cluster 3: macrophage inflammatory protein (MIP)-1α; regulated on activation, normal T cell expressed and secreted (RANTES); eotaxin; and IL-4; all of whose levels were inversely correlated with tumor size and predicted tumor mass across all five treatment combinations (R 2 = 0.69; Fig. 2e,f) .
Motivated by this chemoattractant-rich protective signature, we analyzed cellular infiltrates in treated tumors. AIPV therapy induced tumor infiltration by effector CD4 + and CD8 + T cells, CD11b + Ly6G + Ly6C low neutrophils 25, 26 , NK cells and other myeloid cells (Fig. 3a-d and Supplementary Fig. 6a-d) . PD-1 + TIM-3 + CD8 + T cells were infrequent in all treatment groups, but AIPV treatment induced a large increase in the ratio of CD8 + T cells to regulatory T Mice bearing B16F10 tumors were treated with the regimens indicated, and on day 17 following tumor cell inoculation, tumors were isolated, and cytokine and chemokine levels were measured by Luminex (n = 9 mice per group). Five co-regulated clusters of cytokines and chemokines were identified by hierarchical cluster analysis and then pruning clusters by applying a threshold to linkage distance (c and Supplementary Fig. 5 ). These clusters were independently tested for their ability to predict log-transformed tumor size in treated mice on day 17 using a single latent variable (LV) in an orthogonalized partial least-squares regression (oPLSR) model (d). For the best-performing cluster 3 (red bar), VIP scores (a measure of each cytokine's contribution to the LV score and overall regression performance) were used to assess the contribution of individual proteins from the cluster to the oPLSR model (e); VIP scores >1 (dashed line) were considered significant (top, red bars), and the loading factors for LV1 of the oPLSR model are shown (bottom, red bars). A scatter plot shows the oPLSR cluster 3 model performance for individual mice from all treatment groups and the best fit linear regression (dashed line) (f).
a r t i c l e s nature medicine VOLUME 22 | NUMBER 12 | DECEMBER 2016 1 4 0 5 (T reg ) cells ( Fig. 3c and Supplementary Fig. 6g ,h), a notable outcome given the potential for IL-2 treatment to increase T reg cell numbers. Of interest, however, was that no single leukocyte population examined correlated exactly with therapeutic outcome, as several treatment subcombinations elicited infiltration of individual cell populations equivalent to that with AIPV treatment. Immunohistochemical analysis of tumors from treated mice revealed that CD8 + T cells were present at high density throughout the AIPV-treated tumors, with less effective triple-combination therapies eliciting progressively fewer CD8 + cells in the bulk tumor mass ( Fig. 3e and Supplementary Fig. 6e ,f). Antibody depletion experiments showed that CD8 + T cells were critical to tumor rejection ( Fig. 3f and Supplementary Fig. 7a ). Macrophage, NK cell or neutrophil depletion also led to significant reductions in overall survival rates, whereas IL-5 blockade or CD4 + T cell depletion did not affect efficacy ( Fig. 3f and Supplementary Fig. 7a,b) . Thus, AIPV treatment elicited substantial remodeling of the tumor microenvironment with contributions from diverse effector cells.
Therapy promotes cross-presentation to generate de novo T cell responses
We next assessed whether de novo adaptive immune responses specific for antigens that were not encoded by the vaccine were primed by AIPV treatment. Given the critical role of CD8 + T cells in the therapeutic effect, we first analyzed the effect of AIPV treatment on antigen presentation in the tumor-draining LNs (TDLNs). Batf3 is a transcription factor required for development of cross-presenting dendritic cells (DCs) in mice 27 , and AIPV-treated Batf3 −/− mice failed to reject tumors, indicating a requirement for cross-presenting DCs for the response to therapy (Fig. 4a) . Tumor-specific antibodies promote cross-presentation of tumor antigens 28 . To further explore the role of tumor-specific antibodies in this process, we treated mice bearing GFP-expressing B16F10 tumors with AIPV or with subcombinations of the four components and analyzed the uptake of GFP and fluorescently labeled TA99 in DCs from TDLNs ( Fig. 4b,c) . We examined two Batf3-dependent cross-presenting DC populations that may have distinct roles in tumors, CD8-α + DCs and CD103 + DCs [29] [30] [31] . Labeled TA99 accumulated in these DC populations, and treatment combinations that included TA99 significantly increased GFP uptake by both CD8-α + and CD103 + DCs over that of untreated tumors ( Fig. 4d-g ). Furthermore, ovalbumin (OVA)-expressing B16F10 tumors from mice treated with AIPV (vaccinating against Trp2) induced T cell responses specific for the SIINFEKL OVA peptide that were substantially greater than responses observed in untreated or IPV-treated tumors, indicating a role for the antibody in priming T cell responses to new tumor antigens ( Fig. 4h,i) . Further supporting the conclusion that AIPV treatment induced a broad T cell response to multiple tumor antigens, splenic T cells from B16F10-tumor-bearing mice treated with AIPV produced IFN-γ after restimulation with either parental B16F10 cells or a Trp2-deleted B16F10 cell line ( Supplementary Fig. 8a ,b) ( Fig. 4j,k) . In addition, 50% of AIPV-treated mice that were cured of primary tumors also rejected a re-challenge with Trp2-deleted B16F10 cells on day 125 (Supplementary Fig. 8c ). These data suggest a r t i c l e s that the antibody component of AIPV promoted epitope spreading, leading to functional de novo T cell responses to tumor antigens that were not encoded by the T cell vaccine.
Therapy-induced endogenous antibody responses
In parallel, we evaluated endogenous antibody responses in AIPVtreated mice. In all three transplanted tumor models, AIPV therapy elicited antibodies that bound to the tumor cells (Fig. 5a) . To analyze the endogenous IgG response over time, we developed an approach to deplete the injected antibody from sera recovered from the mice undergoing treatment ( Supplementary Fig. 9a-f) . By using this strategy, we found that both AIPV and the less effective triple subcombinations elicited tumor-specific antibodies, which were detectable as early as 7 d following the start of treatment and that increased in binding signal over 30 d for combinations that promoted better survival ( Fig. 5b and Supplementary Fig. 9f ). An immunoblot with sera from AIPV-treated mice against B16F10 lysate revealed that these endogenous antibodies recognized numerous antigens (Fig. 5c) . These therapy-induced antibodies were functional, as serum transferred from AIPV-treated mice protected naive mice against intravenous B16F10 challenge (Fig. 5d,e) . However, administration of AIPV therapy to B16F10-tumor-bearing µMT mice, which lack mature B cells due to a targeted mutation in immunoglobulin heavy constant mu (Ighm), led to a similar frequency of tumor regressions as that observed in wild-type mice, suggesting that the endogenous antibody response was not essential for the therapeutic effect of the AIPV regimen (Fig. 5f,g ). Taken together, these experiments indicate that AIPV broadly promoted both antibody and T cell responses to epitopes that were not directly targeted by the therapy components.
Efficacy in an autochthonous genetically engineered mouse model Transplanted tumors do not closely mimic the histology of human cancers, and they often have a high mutational burden that generates potential neoantigens. To assess the efficacy of AIPV treatment in a model that more closely mimics the pathophysiology of human disease and to simultaneously determine the effect of a low frequency of neoantigens, we used the Braf CA Pten loxP Tyr::CreER T2 inducible melanoma model 32 (which we hereafter refer to as Braf/Pten mice). In this model, topical application of tamoxifen results in expression of oncogenic Braf V600E and deletion of tumor suppressor gene Pten in melanocytes, resulting in malignant melanoma formation 21-28 d later. We first enhanced the potency of AIPV by increasing the number of antigens targeted by the vaccine component 33 . AIPV therapy using a trivalent amphiphile-vaccine targeting gp100, Trp1 and Trp2 cured 100% of mice bearing B16F10 tumors with mean initial tumor sizes of 50 mm 2 (Fig. 6a,b) . To test this combination in genetically engineered mice, tumors were induced by painting tamoxifen on the ears of Braf/Pten mice, and after visible lesions were present (~4 weeks), treatment was initiated. Melanomas grew progressively, and by week 10 they completely covered the ears of untreated mice (Fig. 6c) . By contrast, trivalentvaccine AIPV promoted regression of induced tumors, leading to clearance of pigmented lesions in the majority of animals and a significant improvement in overall survival as compared to that in untreated mice (Fig. 6c,d ). This result was coincident with the expansion of T cells recognizing the three vaccine-encoded antigens in peripheral blood (Fig. 6e) and with the infiltration of CD8 + T cells throughout tumors of AIPV-treated Braf/Pten mice (Fig. 6f) .
DISCUSSION
To date, complete elimination of large, poorly immunogenic tumors in immunocompetent animal models has only been reliably achieved by combination therapies using large numbers of adoptively transferred T cells 12, 17, 34 . Thus, it has remained an outstanding question whether an endogenous immune response can be stimulated to overcome advanced tumors in a majority of animals. Here we demonstrate the capacity of endogenous immunity, elicited by a safe four-component immunotherapy, to regress large established tumors in the majority of mice in several transplanted models and a genetically engineered model of melanoma. All four components incorporated in AIPV were required for treatment of several difficult-to-treat tumor models, and other treatment combinations were often less effective or very toxic; for example, using anti-CD40 in place of the tumor-specific antibody caused inflammatory toxicity, resulting in death of treated mice (unpublished data). Notably, the models studied here were selected in part due to their resistance to immunotherapy treatment; other commonly used immunogenic tumors (for example, EG7.OVA,
CT26 and MC-38) could be cured by double-or triple-component subcombinations of AIPV (unpublished data).
Many immunotherapy studies focus on CD8 + T cell responses to tumors, but important roles for innate immune effector cells have also been described. Especially in the presence of tumor-opsonizing antibodies, NK cells, neutrophils and macrophages can all contribute to direct antibody-dependent phagocytosis, reactive-oxygen-mediated cytotoxicity against tumors, and secretion of inflammatory cytokines and chemokines [35] [36] [37] . This innate attack creates intertwined positive feedback loops-opsonized tumor antigen is released, which is efficiently cross-presented by DCs 11, 38, 39 ; inflammatory cytokines and immune complexes are released that activate DCs, stimulate their migration to draining LNs and promote adaptive effector functions 21, 40, 41 ; and additional innate effectors and T cells are recruited to the tumor 21, 40, 42 . Consistent with the importance of the innate immune response, maximal efficacy of AIPV therapy was dependent not only on CD8 + T cells but also neutrophils, macrophages, NK cells and cross-presenting DCs. AIPV therapy completely failed in Batf3-deficient mice and was, in fact, even less effective than AIP treatment, suggesting that the loss in efficacy in these knockout animals reflected more than loss of responsiveness to the vaccine component (unpublished data). Although models of infectious disease and systemic immunization have implicated CD8-α + DCs as key crosspresenting cells for T cell immunity 43, 44 , recent data has suggested that in growing tumors, a second Batf3-dependent DC lineage, CD103 + DCs, has a critical role in tumor antigen presentation 29, 30 . Consistent with these reports, we found that both CD8-α + and CD103 + DCs acquired tumor antigen in a manner enhanced by the antibody component of AIPV. Figure 1a , using biotinylated TA99. Mice were bled weekly, and serum was depleted of TA99-biotin using streptavidin resin ( Supplementary  Fig. 9 ). The binding of the remaining endogenous IgG to B16F10 cells was then measured by flow cytometry, as in a. The treatment of multiple tumor models with AIPV therapy revealed distinct hierarchies of importance for the four components. For example, the monoclonal antibody component was a critical contributor to efficacy in the B16F10 model, but it was the least important component in the DD-Her2/neu model. A key aspect of AIPV treatment is that this set of four agents collectively mounts an integrated response that overcomes tumor resistance mechanisms in all of the models evaluated here, suggesting that the appropriate combination of immune effectors can overcome a range of obstacles present in tumor microenvironments. Notably, therapy excluding the extended-halflife IL-2 (APV treatment) showed greatly reduced efficacy in all three transplanted tumor models, correlating with reduced abundance of inflammatory cytokines and chemokines in tumors and fewer infiltrating CD4 + and CD8 + T cells. The cell types that IL-2 must act on for therapeutic efficacy remain to be defined; however, besides supporting the proliferation and effector functions of T cells, IL-2 is known to also drive expansion and enhance the responsiveness of NK cells to target cells 45 , promote neutrophilia and eosinophilia, and induce the production of myriad additional cytokines and chemokines that may support a combined innate and adaptive immune attack on tumors 46 . Despite the potential of IL-2 to expand T reg cells, we found that intratumoral CD8:T reg cell ratios were amplified relative to those in untreated tumors during AIPV therapy.
Although it remains an understudied area, prior work has demonstrated that the number of antigens targeted by cancer vaccines can be an important variable, with vaccines targeting more antigens leading to greater antitumor efficacy 33 . In agreement with these data, we found that the efficacy of AIPV therapy was sensitive to the valency of the vaccine; targeting a single epitope in the B16F10 model led to a 75% cure rate (Fig. 1c) , whereas a modest increase in vaccine valency to target three melanocyte antigens led to cures in 100% of treated mice (Fig. 6a,b) . There is currently much enthusiasm for targeting neoantigens formed by mutations in tumors, but our data demonstrate that combination immunotherapy targeting only tumor-associated self-antigens can elicit pronounced tumor regressions, even in the setting of a genetically induced mouse model bearing an intrinsically low burden of mutations. However, AIPV treatment also promoted responses to additional antigens not present in the vaccine, which could protect against challenge with tumor cells lacking the vaccinetargeted antigens. We attempted to evaluate whether AIPV could be protective in the absence of antigen spreading by treating T cell receptor (TCR)-transgenic pmel-1 mice 17 , which lack T cells capable of responding to peptides other than gp100; however, AIPV treatment of these mice using a vaccine specific for gp100 elicits severe inflammatory toxicity (unpublished observation). Antigen spreading promoted by immunotherapy has also been observed in recent clinical studies of patients with melanoma 47 , and it may be important for dealing with tumor heterogeneity and preventing escape by tumor antigen loss variants 48 . Endogenous antibody responses were primed by AIPV and other combinations of the four monotherapies, and AIPV treatment induced antibodies that were protective when transferred to naive recipients. Despite these findings, B cells were not required for AIPV treatment efficacy. We speculate that because the therapy itself includes a potent monoclonal tumor-opsonizing antibody, the endogenous response may be dispensable. An interesting question for future work will be whether the monoclonal antibody component can be removed from the treatment regimen after the endogenous antibody response develops, i.e., by the second or third treatment.
AIPV incorporates two tumor-specific reagents, the LN-targeted peptide vaccine and a monoclonal opsonizing antibody. Although it is still a challenge in some diseases, identification of T cell target antigens that are shared by a proportion of tumors of a given type has been well delineated for many cancers over the past 20 years by the cancer vaccine field 49 , and a number of pipelines for finding unique mutant neoantigens have recently been developed 50, 51 . In contrast, identifying an effective opsonizing monoclonal antibody presents a development hurdle for applying AIPV therapy to an arbitrary given tumor. However, the demonstration that the integrin-binding protein 2.5F-Fc, which contains an Fc domain for antibody effector functions and which recognizes the α v β 3 , α v β 5 , and α 5 β 1 integrins (which are overexpressed in a broad range of cancers 52 ), suggests that the 2.5F-Fc protein may be applicable to many tumor types. Careful consideration of potential side effects is needed in the choice of target antigens for translation of this approach. Targeting tumorassociated antigens carries the risk of autoimmunity; for example immunotherapy targeting melanocyte self-antigens is known to induce vitiligo, uveitis and hearing loss in some patients due to loss of normal melanocytes 53, 54 . Sequencing of patient tumors for neoantigen identification is an attractive alternative, and the peptide vaccine platform used here is well suited to such an approach. Similarly, although antigen spreading as observed here may promote tumor rejection, an important issue for future work is understanding whether these de novo T cell responses are focused on tumor-specific mutations or on self-antigens.
In summary, we have demonstrated that a rational combination of four complementary immunomodulatory agents, each of which have modest antitumor efficacy individually, can lead to robust complete responses in the setting of large, immunosuppressive tumors. Rejection of established tumors relied on an orchestrated response invoking diverse effector mechanisms of the immune system. Although using a quaternary treatment regimen will be challenging for direct clinical translation because of the complexity of identifying optimal dosing levels and schedules for each component, insights from this successful protocol provide a framework for devising simpler regimens and extensions to other treatment modalities.
METHODS
Methods and any associated references are available in the online version of the paper. Cells. B16F10 cells were purchased from ATCC. TC-1 cells were kindly provided by T.C. Wu (Johns Hopkins University). B16-OVA and DD-Her2/neu cells were kindly provided by G. Dranoff (Dana-Farber Cancer Center). B16-GFP-Luc cells were generated as previously described 55 . DD-Her-2/neu breast tumor cells were derived from a spontaneous breast tumor in a Balb/c Her-2/neu (Balb-NeuT) transgenic mouse, in which mouse mammary tumor virus (MMTV)-promoterdriven breast-epithelium-specific expression of the activated oncogenic form of rat Her-2/neu drives progressive development of breast tumors in transgenic Her-2/neu female mice 56 . The DD cell line was found to lose Her-2/neu expression in vitro, and thus cells were infected with the pMFG-Her-2/neu virus to achieve stable expression of high levels of oncogenic rat Her-2/neu both in vitro and in vivo. HEK293 cells were purchased from Life Technologies.
Tumor cell lines were cultured in complete Dulbecco's modified Eagle's medium (DMEM, GE Healthcare Life Sciences; supplemented with 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, and 4 mM l-alanyl-lglutamine) with the exception of TC-1 cells, which were cultured in complete RPMI medium (GE Healthcare Life Sciences). T cells and splenocytes were cultured in RPMI with 10% heat-inactivated FBS, 20 mM HEPES, 1 mM sodium pyruvate, 0.05 mM β-mercaptoethanol, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM l-alanyl-l-glutamine, and 1× minimal essential medium (MEM) non-essential amino acids. Hybridomas were cultured in CD Hybridoma AGT Medium (Life Technologies). HEK293 cells were cultured in Freestyle medium (Life Technologies). All cell lines and assay cultures were maintained at 37 °C and 5% CO 2 . All cells were tested regularly for mycoplasma contamination and for rodent pathogens, and none used tested positive at any point.
Vaccine and protein production. Amphiphile-CpG (amph-CpG) was produced, as previously described, by solid-phase synthesis of a class B CpG 1826 oligonucleotide with G 2 spacer (5′-diacyl lipid-*G*G*T*C*C*A*T*G*A* C* G*T*T*C*C*T*G*A*C*G*T*T-3′) conjugated via the 5′ end to an 18-carbon diacyl tail 10 . Amphiphile-peptides (amph-peptides) were produced as previously described 10 57 , CTAPDNLGYM), gp100 opt20-39 (optimized S27P, EGP long 58 , CAVGALEGPRNQDWLGVPRQL). TA99 and MSA-IL-2 were produced in HEK293 cells as previously described 9 . 2.5-Fc was generated by fusing an integrin (α V β 3 , α V β 5 , and α 5 β 1 )-binding domain to a mouse IgG2a Fc region to create an antibody-like tumor-targeting molecule 23 . 2.5-Fc was produced by transient transfection of HEK293 cells and purified using protein A. The 7.16.4 monoclonal antibody to rat Her2/neu was generated from hybridoma 7.16.4 (purchased from ATCC) and purified by using protein A. IFN-α was expressed as a SUMO fusion using the pE-SUMOpro vector (LifeSensors) in Rosetta-gami 2 (DE3) competent cells (Novagen). After immobilized metal-affinity column purification using TALON metal-affinity resin according to the manufacturer's instructions (Clontech Laboratories), the SUMO tag was removed by incubation with SUMO protease and reapplication on TALON resin as detailed previously 59 . Finally, the protein was passed through Detoxi-Gel endotoxin removal resin (Thermo Scientific) until endotoxin levels were below 0.1 total EU/dose as measured by the QCL-1000 chromogenic LAL assay (Lonza). The IL-15 superagonist 60 was produced by transiently transfecting HEK293 cells with a plasmid encoding histidine (His)-tagged IL-15 superagonist and purified using Ni-NTA agarose (Qiagen) on a PD-10 column (Bio-Rad) followed by further purification using a His-Spin Protein Miniprep (Zymo Research). Anti-TGF-β, a homodimeric fusion between murine IgG2a Fc and the extracellular domain of the type II TGF-β receptor, was produced by transient transfection of HEK293 cells and purified by protein A.
Tumor inoculation and subcutaneous tumor therapy. An inoculum of 10 6 tumor cells was injected s.c. on the flank of mice in 50 µl sterile PBS. Eight days following injection, treatment was initiated as indicated (Fig. 1a) . The tumortargeting antibody (A) was administered at 100 µg per dose (i.p.) for the B16F10 and DD-Her2/neu models. 2.5-Fc was administered at 500 µg per dose (i.p.). MSA-IL2 (I) was administered i.p. at 30 µg (6 µg molar equivalent IL-2) per dose. Anti-PD-1 (P) (clone RMP1-14, BioXCell) was administered at 200 µg (i.p.). The vaccine, composed of 1.24 nmol amph-CpG and 20 µg of amph-peptide, was administered s.c. at the base of the tail, with half of the dose given on each side. For experiments exploring other quaternary combos, the following doses were used as indicated in Supplementary Figure 3: anti-CTLA-4 (clone 9D9, BioXCell) was administered at 200 µg per dose i.p.; IFN-α was administered at 50 µg per dose i.p.; IL-15 superagonist was administered at 4 µg per dose i.p.; and anti-TGF-β was administered at 100 µg per dose i.p. Mice were randomized into treatment groups on day 8 following tumor inoculation, immediately before treatment. Tumor size was measured as an area (longest dimension × perpendicular dimension) three times weekly, and mice were euthanized when tumor area exceeded 100 mm 2 . Mice that rejected tumors were re-challenged as indicated with 10 5 tumor cells by subcutaneous injection on the opposite flank.
Flow cytometry. Antibodies to CD8-α (53-6.7), IFN-γ (XMG1.2), TNF-α (MP6-XT22), CD3-ε (500A2), IgM (RMM-1), CD19 (6D5), NK1.1 (PK136), Ly-6G (1A8), F4/80 (BM8), CD11b (M1/70), CD25 (PC61), PD-1 (29F.1A12), Tim-3 (B8.2C12), Ly-6C (HK1.4) and CD64 (X54-5/7.1) were purchased from BioLegend. Antibodies to CD4 (RM4-5) and Foxp3 (FJK-16s) were purchased from eBioscience. Trp2 tetramer (iTAg Tetramer/PE H-2K b TRP2) and OVA tetramer (iTAg Tetramer/PE H-2K b OVA) were purchased from MBL. Tetramer staining was performed in buffer containing 50 nM dasatinib to enhance staining. Viability was assessed by LIVE/DEAD Fixable Aqua (Life Technologies). TA99 was labeled with Alexa Fluor 647 NHS Ester (Life Technologies) to generate TA99-647. Foxp3 was stained using the Transcription Factor Buffer Set from BD.
Intracellular cytokine staining (ICS) was performed as described previously 10 . Peptides used for restimulation were 10 µg/ml of the relevant antigen: Trp2 180-188 (SVYDFFVWL), Her2/Neu 66-74 (TYVPANASL), Tyrp-1 455-463native (TAPDNLGYA), or gp100 25-33native (EGSRNQDWL) . Immune cell infiltrates of tumors were analyzed as previously described 9 ; briefly, tumors were resected from mice on day 14 or 21, weighed, and mechanically disrupted to generate a single-cell suspension. Cells were stained to identify infiltrating immune cells and quantified using flow cytometry. Shown are cell counts normalized by tumor mass. For antibody-and GFP-uptake experiments, lymph nodes were resected from tumor-bearing mice on day 10, digested with collagenase and dispase in the medium at 37 °C for 20 min, and mechanical disruption was used to generate a single-cell suspension. Cells were stained to identify DC populations and run on the cytometer. Cells were analyzed using BD FACS LSR II, BD FACS LSR Fortessa, and BD FACSCanto flow cytometers, and data were analyzed using FlowJo.
Depletions. Cellular subsets were depleted by administering 400 µg of depleting antibody i.p. twice weekly beginning 1 d before therapy as indicated: CD8 T cells with anti-CD8-α (clone 2.43, BioXCell), CD4 T cells with anti-CD4 (clone GK1.5, BioXCell), NK cells with anti-NK1.1 (clone PK136, BioXCell), neutrophils with anti-Ly-6G (clone 1A8, BioXCell). Macrophages or eosinophils were depleted using 300 µg anti-CSF1R (clone AFS98, BioXCell) every other day or 1 mg anti-IL-5 (clone TRFK5, BioXCell) weekly, respectively 9 . Cellular depletions of CD8 T cells, CD4 T cells, neutrophils and NK cells were confirmed by flow cytometry of PBMC (Supplementary Fig. 7 ).
